Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Drug Development
Drug Development · The big question

Click Chemistry Speeds Up the Hunt for Targeted Cancer Drugs

Integrated Strategic Design and In Situ Click Chemistry Approach to Rapid Discovery of Novel Potent Covalent TEAD Inhibitors.

PubMed1 min readAI-assisted summary
Editorial illustration for Integrated Strategic Design and In Situ Click Chemistry Approach to Rapid Discovery of Novel Potent Covalent TEAD Inhibitors.
Editorial illustration

Summary

Proteins known as TEAD act as dangerous switches inside our cells. When activated by partner proteins, they become oncogenic drivers, meaning they fuel the growth of cancer. Finding drugs to block them has historically been a slow process because traditional methods rely on randomly testing massive libraries of chemical compounds, which is highly inefficient.

To speed up the search, researchers combined structural biology with a highly efficient molecular building technique. This method allowed them to rapidly construct a customized library of chemical fragments designed to tightly bind to specific, water-repelling pockets on the TEAD protein. By screening these new compounds immediately as they were made, the team achieved an impressive 8.33 percent success rate in identifying potential inhibitors.

The most promising compound to emerge from this rapid screening was a molecule named LC-TEAD01. Structural tests confirmed that it permanently latches onto a specific amino acid called a cysteine deep inside the protein. This physical roadblock successfully stops the cancer-driving proteins from interacting. When tested in living animal models missing a key tumor-suppressing gene called NF2, the new drug effectively halted tumor growth.

Why it matters.

This integrated strategy offers a powerful new tool for the pharmaceutical industry. Designing drugs from scratch is notoriously slow, but this blueprint provides a fast, repeatable way to discover highly selective medications. The researchers note that this approach is generalizable, meaning scientists could use it to quickly find chemical inhibitors for almost any disease-causing protein that features a well-defined pocket.

For patients with cancers driven by specific genetic profiles, such as NF2 mutations, this work points to promising future therapies. However, this study represents early preclinical research. While LC-TEAD01 successfully shrank tumors in animal models and biochemical tests, it must undergo years of rigorous evaluation and human clinical trials before it can be prescribed in a clinic.

From the source

The story in numbers.

Screening hit rate
8.33%
Preference for NF2-deficient NCI-H226 cells
17-fold
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Drug Development

A $122M boost for a fast, inside-the-body approach to cell therapy

Create Medicines recently secured $122 million to advance a new class of treatments for cancer and autoimmune diseases. They specialize in CAR-T cell therapy, a treatment that engineers the immune system to fight disease. But instead of the traditional method of removing cells from a patient to alter them in a lab, Create Medicines is developing therapies that work entirely inside the body, a process known as "in vivo" treatment. To achieve this, the therapy uses tiny fat bubbles called lipid nanoparticles to deliver messenger RNA, or mRNA, into the patient. Think of mRNA as a set of biological instructions. Once delivered, these instructions directly teach the patient's existing immune cells, including T cells, natural killer cells, and myeloid cells, to reprogram themselves into disease fighters. The startup has already dosed more than 50 patients, giving it the largest clinical dataset in the in vivo field. They recently began an early-stage clinical trial for an experimental therapy designed to attack solid tumors that carry a specific protein called HER2. Alongside this cancer research, the company is testing other treatments that target proteins called CD19 and BCMA to help patients with autoimmune conditions.

BioPharma Dive1 min read
Drug Development

Supreme Court Protects Access to Common Abortion Pill

The United States Supreme Court has decided to preserve access to mifepristone, a medication used in the most common method of abortion. By rejecting recent restrictions proposed by lower courts, the Supreme Court has ensured that patients can still obtain this widely used drug while an ongoing lawsuit continues to make its way through the legal system. Under this current legal order, patients do not need an in-person visit with a doctor to get the medication. Instead, they are permitted to continue receiving mifepristone directly from pharmacies or through the mail. This ruling maintains the existing distribution methods, meaning that access is expected to remain uninterrupted at least into the following year as further legal proceedings unfold.

STAT News1 min read
Drug Development

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

What if a medical implant could sense an infection and fight it off automatically? Researchers have created exactly that with a new technology called an "implantable living material." To build it, scientists used a specialized, water-based gel known as a polyvinyl alcohol hydrogel. This material acts as a tiny, flexible fortress. It is uniquely stiff and tough, designed to hold genetically engineered bacteria safely inside for up to six months without them escaping into the surrounding tissue. Inside this protective gel, the researchers trapped a modified version of E. coli bacteria to act as molecular guards. These engineered microbes are programmed to detect chemical signals given off by Pseudomonas aeruginosa, a dangerous pathogen that frequently causes infections around artificial joints. When the trapped bacteria sense the invader, they trigger a targeted self-destruct mechanism. This intentional cellular explosion releases a powerful antibacterial protein that easily passes through the microscopic pores of the gel to kill the infection outside. The research team tested this system in mice with artificial joint infections. Over a three-day treatment period, the living implant significantly reduced the amount of infectious bacteria compared to non-therapeutic controls. By keeping the helpful microbes physically contained while allowing their medicine to flow out, the researchers have found a clever way to turn living cells into localized drug factories.

GEN2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
Click Chemistry Speeds Up the Hunt for Targeted Cancer Drugs — Daily Strand